← FDA DRUG APPROVALS

FDA ANDA · ANDA210191

DAPSONE

Sponsor: SUN PHARMA CANADA

APPLICATION
ANDA210191
TYPE
ANDA
ORIGINAL APPROVAL
2019-06-26
LATEST ACTION
2023-02-27
ROUTE
TOPICAL
DOSAGE FORM
GEL
MARKETING STATUS
Prescription

Products

DAPSONEPrescription
DAPSONE 7.5% · GEL · TOPICAL

Approval history

2023-02-27Labeling · Supplement 2 · standardAP
2023-02-27Labeling · Supplement 3 · standardAP
2019-06-26UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →